Sun Pharma Q2 Results: Revenue from operations rose 12% YoY to Rs 16,199 crore from Rs 14,478 crore in Q2 of last financial year, supported by strong growth in its domestic formulations business and emerging markets.
The stock market in India has encountered a rough patch, evidenced by the Nifty’s decline of over 11% since last Diwali. However, smallcap stocks have
In 2026, the Nifty 50 index faced significant drops, with 34 out of 50 stocks plummeting by as much as 34%. Analysts believe that the
Advertiser Disclosure
Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.
Disclaimer
It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information.
The information on this website does not constitute investment advice or a recommendation or a solicitation to engage in any investment activity. This website and its content are not intended for residents of the UAE, US, Canada, Australia, UK, Russia, North Korea, China, Japan, Hong Kong, Singapore and Iran.
Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003